Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 2
2003 2
2004 3
2005 11
2006 7
2007 4
2008 2
2009 4
2010 8
2011 21
2012 17
2013 16
2014 16
2015 15
2016 10
2017 7
2018 8
2019 5
2020 11
2021 6
2022 13
2023 9
2024 12

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF; KEYNOTE-045 Investigators. Bellmunt J, et al. N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17. N Engl J Med. 2017. PMID: 28212060 Free PMC article. Clinical Trial.
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U, Bögemann M, Bamias A, Eigl BJ, Gurney H, Mukherjee SD, Fradet Y, Skoneczna I, Tsiatas M, Novikov A, Suárez C, Fay AP, Duran I, Necchi A, Wildsmith S, He P, Angra N, Gupta AK, Levin W, Bellmunt J; DANUBE study investigators. Powles T, et al. Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
The role of microRNAs in bladder cancer.
Enokida H, Yoshino H, Matsushita R, Nakagawa M. Enokida H, et al. Investig Clin Urol. 2016 Jun;57 Suppl 1(Suppl 1):S60-76. doi: 10.4111/icu.2016.57.S1.S60. Epub 2016 Jun 7. Investig Clin Urol. 2016. PMID: 27326409 Free PMC article. Review.
Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy.
Shiota M, Takamatsu D, Matsui Y, Yokomizo A, Morizane S, Saito R, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Narita S, Edamura K, Yamaguchi T, Hashimoto K, Kato M, Kasahara T, Yoshino T, Akamatsu S, Kaneko T, Matsukawa A, Matsumoto R, Joraku A, Saito T, Kato T, Kato M, Enokida H, Sakamoto S, Terada N, Kanno H, Nishiyama N, Kimura T, Kitamura H, Eto M; Japanese Urological Oncology Group. Shiota M, et al. Among authors: enokida h. Ann Surg Oncol. 2024 Jun;31(6):3872-3879. doi: 10.1245/s10434-024-14999-2. Epub 2024 Feb 14. Ann Surg Oncol. 2024. PMID: 38353798
Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models.
Kawahara I, Yoshino H, Fukumoto W, Arima J, Saito S, Li G, Fukuda I, Mitsuke A, Sakaguchi T, Inoguchi S, Matsushita R, Nakagawa M, Tatarano S, Yamada Y, Enokida H. Kawahara I, et al. Among authors: enokida h. Mol Oncol. 2024 Sep;18(9):2196-2211. doi: 10.1002/1878-0261.13684. Epub 2024 Jun 14. Mol Oncol. 2024. PMID: 38874588 Free PMC article.
Aberrant expression of microRNAs in bladder cancer.
Yoshino H, Seki N, Itesako T, Chiyomaru T, Nakagawa M, Enokida H. Yoshino H, et al. Among authors: enokida h. Nat Rev Urol. 2013 Jul;10(7):396-404. doi: 10.1038/nrurol.2013.113. Epub 2013 May 28. Nat Rev Urol. 2013. PMID: 23712207 Review.
Laparoscopic Surgery for Pheochromocytoma in Hemodialysis Patients.
Tatarano S, Mitsuke A, Sakaguchi T, Matsushita R, Inoguchi S, Yoshino H, Nishimura H, Yamada Y, Enokida H. Tatarano S, et al. Among authors: enokida h. Int J Nephrol. 2022 Jul 21;2022:3060647. doi: 10.1155/2022/3060647. eCollection 2022. Int J Nephrol. 2022. PMID: 35910424 Free PMC article.
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
Yokomizo A, Shiota M, Morokuma F, Eto M, Matsuyama H, Matsumoto H, Kamoto T, Terada N, Kawahara K, Enokida H, Tatarano S, Fujimoto N, Higasijima K, Sakai H, Hakariya T, Igawa T, Suekane S, Kamba T, Sugiyama Y, Kishimoto J, Naito S. Yokomizo A, et al. Among authors: enokida h. Int J Urol. 2024 Apr;31(4):362-369. doi: 10.1111/iju.15371. Epub 2023 Dec 26. Int J Urol. 2024. PMID: 38148124 Clinical Trial.
Epigenetics in bladder cancer.
Enokida H, Nakagawa M. Enokida H, et al. Int J Clin Oncol. 2008 Aug;13(4):298-307. doi: 10.1007/s10147-008-0811-1. Epub 2008 Aug 15. Int J Clin Oncol. 2008. PMID: 18704629 Review.
183 results